Search

Your search keyword '"030211 gastroenterology & hepatology"' showing total 1,339 results

Search Constraints

Start Over You searched for: Descriptor "030211 gastroenterology & hepatology" Remove constraint Descriptor: "030211 gastroenterology & hepatology" Topic medicine.disease Remove constraint Topic: medicine.disease Journal journal of hepatology Remove constraint Journal: journal of hepatology
1,339 results on '"030211 gastroenterology & hepatology"'

Search Results

1. Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma

2. Development and validation of a new prognostic score for hepatitis B virus-related acute-on-chronic liver failure

3. Polyploidy control in hepatic health and disease

4. Non-alcoholic fatty liver disease in children and young adults is associated with increased long-term mortality

5. Why are there so many liver transplants from living donors in Asia and so few in Europe and the US?

6. Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: Data from Global Burden of Disease 2009-2019

7. Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load

8. Linkage of resistance-associated substitutions in GT1 sofosbuvir + NS5A inhibitor failures treated with glecaprevir/pibrentasvir

9. Dual and opposing roles of the androgen receptor in VETC-dependent and invasion-dependent metastasis of hepatocellular carcinoma

10. Prognosis of French COVID-19 patients with chronic liver disease: A national retrospective cohort study for 2020

11. Dysregulation of the ESRP2-NF2-YAP/TAZ axis promotes hepatobiliary carcinogenesis in non-alcoholic fatty liver disease

12. Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy

13. Falls are common, morbid, and predictable in patients with cirrhosis

14. Early liver transplantation for acute alcoholic hepatitis: We can’t say no

15. Global burden of acute viral hepatitis and its association with socioeconomic development status, 1990–2019

16. CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis

17. Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis

18. Muscle fat content is strongly associated with NASH: A longitudinal study in patients with morbid obesity

19. Towards personalised medicine in autoimmune hepatitis: Measurement of thiopurine metabolites results in higher biochemical response rates

20. The mitochondrial dicarboxylate carrier prevents hepatic lipotoxicity by inhibiting white adipocyte lipolysis

21. Current knowledge and management of portal vein thrombosis in cirrhosis

22. A notable proportion of liver transplant candidates with alcohol-related cirrhosis can be delisted because of clinical improvement

23. FOXA3 induction under endoplasmic reticulum stress contributes to non-alcoholic fatty liver disease

24. Long-term effectiveness of population-wide multifaceted interventions for hepatocellular carcinoma in Taiwan

25. A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis

26. Transition to decompensation and acute-on-chronic liver failure: Role of predisposing factors and precipitating events

27. CAD-LT score effectively predicts risk of significant coronary artery disease in liver transplant candidates

28. Sarcopenia and frailty in decompensated cirrhosis

29. Limitations of current liver donor allocation systems and the impact of newer indications for liver transplantation

30. Safety and efficacy of in vitro fertilisation in patients with chronic liver disease and liver transplantation recipients

31. Cost-effectiveness of alcohol use treatments in patients with alcohol-related cirrhosis

32. Association of liver abnormalities with in-hospital mortality in patients with COVID-19

33. Predicting survival after liver transplantation in patients with hepatocellular carcinoma using the LiTES-HCC score

34. Endpoints in clinical trials for liver cancer and their value in evidence-based clinical decision making: An unresolved Gordian knot

35. Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB/c.Abcb4 mouse model of PFIC3

36. Early liver transplantation for corticosteroid non-responders with acute severe autoimmune hepatitis: The SURFASA score

37. Targeting Nestin+ hepatic stellate cells ameliorates liver fibrosis by facilitating TβRI degradation

38. Integrative molecular characterisation of gallbladder cancer reveals micro-environment-associated subtypes

39. Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease

40. Acetylation of lactate dehydrogenase B drives NAFLD progression by impairing lactate clearance

41. The changing context of hepatitis D

42. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity

43. Systemic treatment of HCC in special populations

44. A novel waitlist dropout score for hepatocellular carcinoma – identifying a threshold that predicts worse post-transplant survival

45. Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality

46. Predicting the risk of post-hepatectomy portal hypertension using a digital twin: A clinical proof of concept

47. Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy

48. A global investment framework for the elimination of hepatitis B

49. Hepatitis C viraemic organs in solid organ transplantation

50. IL-2 contributes to cirrhosis-associated immune dysfunction by impairing follicular T helper cells in advanced cirrhosis

Catalog

Books, media, physical & digital resources